Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.88 |
| ▸ | MAOB | P27338 | 5/20 | 0.83 |
| ▸ | MAOA | P21397 | 3/20 | 0.83 |
| ▸ | GUSB | P08236 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085108 | 1.00 | AR (0.88) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL5087961 | 0.91 | MAOB (1.00) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL5087952 | 0.91 | MAOB (1.00) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL10830261 | 0.91 | AR (0.78) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL10830021 | 0.90 | AR (1.00) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL11050763 | 0.90 | AR (1.00) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL28906329 | 0.90 | AR (0.76) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL5085079 | 0.89 | MAOB (0.86) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL5437092 | 0.89 | MAOB (0.86) | ARMAOBMAOAGUSBMAPT | |
| SCHEMBL5424561 | 0.88 | MAOB (0.74) | ARMAOBMAOAGUSBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-4461907-A | Amino-substituted flavans useful as anti-viral agents | BURROUGHS WELLCOME CO. | 1984-07-24 | — | — | US | disclosed |
| EP-0004579-B1 | FLAVANS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-08-18 | — | — | EP | disclosed |
| EP-0004579-A1 | Flavans, process for their preparation and pharmaceutical compositions containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | AR 152/4885MAOB 1213/4885MAOA 1628/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | AR 143/4885MAOB 3735/4885MAOA 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.